Context Therapeutics Stockholders Approve Increase in Authorized Common Stock to 300 Million

Context Therapeutics Inc. announced that its stockholders have approved an amendment to the company's Certificate of Incorporation to increase the number of authorized shares of common stock. The approval was granted during the Annual Meeting of Stockholders held on June 24, 2026.

Key Details

• Share Increase: The number of authorized shares of common stock was increased by 50%, from 200,000,000 to 300,000,000.
• Effective Date: The amendment was filed with the Secretary of State of Delaware and became effective on June 24, 2026.
• Other Meeting Outcomes: Stockholders also elected seven director nominees to the Board of Directors and ratified the selection of CohnReznick LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026.